Compare OOMA & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OOMA | BCYC |
|---|---|---|
| Founded | 2003 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 408.2M | 360.7M |
| IPO Year | 2015 | 2019 |
| Metric | OOMA | BCYC |
|---|---|---|
| Price | $14.41 | $4.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $18.77 | $14.00 |
| AVG Volume (30 Days) | 232.2K | ★ 567.5K |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 188.46 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $114,490,000.00 | N/A |
| Revenue This Year | $20.35 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $63.65 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $9.79 | $4.24 |
| 52 Week High | $15.15 | $9.55 |
| Indicator | OOMA | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 50.38 |
| Support Level | $10.95 | $4.24 |
| Resistance Level | $14.83 | $7.14 |
| Average True Range (ATR) | 0.50 | 0.29 |
| MACD | -0.04 | 0.09 |
| Stochastic Oscillator | 56.32 | 81.56 |
Ooma Inc is a communications services company. It is a smart software-as-a-service (SaaS) and unified communications platform that deliver voice and collaboration features including messaging, intelligent virtual attendants and video conferencing, and residential phone service provides PureVoice high-definition voice quality, advanced functionality and integration with mobile devices. Its services rely upon the following main elements: multi-tenant cloud service, on-premise devices, desktop and mobile applications, and calling platforms. It generates revenues from the sale of subscriptions and other services.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.